Media releases

Press release
- 29.02.2024

Rare Disease Day 2024 – Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy

Press release
- 26.02.2024

Neuraxpharm announces the first launch of BRIUMVI® (ublituximab) in Europe for the treatment of relapsing multiple sclerosis

Press release
- 26.01.2024

EU regulatory review update of leriglitazone: A re-examination for cerebral adrenoleukodystrophy (cALD) will be requested following the negative CHMP opinion.

Announcement
- 20.12.2023

European Commission revokes all centrally granted generic marketing permissions for dimethyl fumarate (“DMF”), including Dimethyl Fumarate Neuraxpharm

Press release
- 01.08.2023

TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)

Press release
- 11.07.2023

Neuraxpharm expands outside Europe into Brazil and Mexico

Press release
- 06.06.2023

Neuraxpharm expands Greek product portfolio with acquisition of Lazap®, a well-established antipsychotic brand

Press release
- 04.05.2023

Neuraxpharm rebrands Laboratorios Lesvi as Neuraxpharm Pharmaceuticals S.L.

Press release
- 27.04.2023

Neuraxpharm agrees on the divestment of inhalation API specialist Inke to Keensight Capital

Press release
- 25.04.2023

Minoryx presents positive interim results from NEXUS registration study for leriglitazone

View more

Media Enquiries

If you are a journalist with a media enquiry, please contact the Neuraxpharm media office by filling the contact form.

CNS

Neuraxpharm

Support

Linkedin Youtube

Join our mailing list

Get the latest updates from the Neuraxpharm.